Researchers have found that combining ipilimumab (YervoyTM) and vemurafenib (Zelboraf®) can cause side effects for patients with metastatic melanoma. This research is reported in a letter in the April 4, 2013, issue of the New England Journal of Medicine by Memorial Sloan Kettering medical oncologist Jedd Wolchok, medical oncologist and research fellow Margaret Callahan, and colleagues from Memorial Sloan Kettering, Dana Farber Cancer Institute, and the University of California, Los Angeles.